HALOZYME THERAPEUTICS, INC. (HALO)
Data as of , from SEC Form 4 filings.
See up to 3 months of HALO. The 7-day demo opens the 1M and 3M ranges and puts HALO on your watchlist.
Start 7-day demoLatest HALO insider trades
About HALOZYME THERAPEUTICS, INC. (HALO)
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- SAN DIEGO, CA
- 423
- 2004
- XNAS
HALO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 39 | 205,852 | $22.10M |
| Grant or award | 5 | 9,679 | |
| Option exercise | 18 | 360,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
HALO insider transactions (Form 4)
2969 Form 4 filings on record, the earliest from Oct 9, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mahesh Krishnan | Grant or award | Common Stock | 4,165 | $0.00 | - | |
| Mahesh Krishnan | Grant or award | Option to Purchase Common Stock | 5,750 | $0.00 | - | |
| Bernadette Connaughton | Grant or award | Common Stock | 4,165 | $0.00 | - | |
| Bernadette Connaughton | Grant or award | Option to Purchase Common Stock | 5,750 | $0.00 | - | |
| Barbara Gayle Duncan | Grant or award | Common Stock | 4,165 | $0.00 | - | |
| Barbara Gayle Duncan | Grant or award | Option to Purchase Common Stock | 5,750 | $0.00 | - | |
| Jeffrey William Henderson | Open-market sale | Common Stock | 4,297 | $60.34 | $259K | |
| Jeffrey William Henderson | Open-market sale | Common Stock | 200 | $61.00 | $12K | |
| Jeffrey William Henderson | Open-market sale | Common Stock | 503 | $64.05 | $32K | |
| Helen Torley - Officer | Gift | Common Stock | 10,000 | $0.00 | - | |
| Connie Matsui | Gift | Common Stock | 10,470 | $0.00 | - | |
| Michael J. Labarre - Officer | Option exercise | Common Stock | 5,509 | $16.65 | $92K | |
| Michael J. Labarre - Officer | Option exercise | Common Stock | 4,491 | $19.98 | $90K | |
| Michael J. Labarre - Officer | Open-market sale | Common Stock | 9,923 | $53.74 | $533K | |
| Michael J. Labarre - Officer | Open-market sale | Common Stock | 77 | $54.25 | $4K | |
| Michael J. Labarre - Officer | Option exercise | Common Stock | 10,000 | $19.98 | $200K | |
| Michael J. Labarre - Officer | Open-market sale | Common Stock | 10,000 | $53.26 | $533K | |
| Michael J. Labarre - Officer | Option exercise | Option to Purchase Common Stock | 5,509 | $0.00 | - | |
| Michael J. Labarre - Officer | Option exercise | Option to Purchase Common Stock | 4,491 | $0.00 | - | |
| Michael J. Labarre - Officer | Option exercise | Option to Purchase Common Stock | 10,000 | $0.00 | - | |
| Helen Torley - Officer | Option exercise | Common Stock | 10,000 | $13.87 | $139K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 9,100 | $53.94 | $491K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 900 | $54.57 | $49K | |
| Helen Torley - Officer | Option exercise | Common Stock | 10,000 | $13.87 | $139K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 5,981 | $51.85 | $310K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 1,615 | $53.31 | $86K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 2,404 | $53.91 | $130K | |
| Helen Torley - Officer | Option exercise | Option to Purchase Common Stock | 10,000 | $13.87 | $139K | |
| Helen Torley - Officer | Option exercise | Option to Purchase Common Stock | 10,000 | $13.87 | $139K |
Recent HALO Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| MATTHEW POSARD | Director | 34,226 | $3.64M | View on EDGAR | |
| Helen Torley | President, CEO, Director | 240,000 |
Stock trades in HALO disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.Democrat, CA-31 | Sale (partial) |
HALO insider trading FAQ
What is the latest insider trade for HALO?
HALOZYME THERAPEUTICS, INC. (HALO) had 9 insider filings in the last 90 days, with the most recent on 2026-10-08. The full record for HALO runs to 69 Form 4 filings, the earliest from 2024-10-09. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying HALO stock?
No insider purchases of HALO were filed in the last 90 days.
How many insiders are selling HALO stock?
39 insider sales of HALO were filed in the last 90 days, totaling $22.10M.
Where can I see HALO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects HALO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Helen Torley view on EDGAR
- - Bernadette Connaughton view on EDGAR
- - James M. Daly view on EDGAR
- - Matthew L. Posard view on EDGAR
- - Matthew L. Posard view on EDGAR
- - Helen Torley view on EDGAR
- - Dannielle Appelhans view on EDGAR
- - Helen Torley view on EDGAR
- - Bernadette Connaughton view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where HALO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow HALO with a 7-day demo
- HALO on your watchlist
- Every HALO Form 4 filing on record
- Up to 3 months of HALO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
